Arno Therapeutics, Inc.'s ongoing phase 2 clinical trial evaluating the combination of onapristone plus Zytiga® (abiraterone acetate) in patients with CRPC has completed the lead-in phase at 30 mg BID of onapristone plus full dose abiraterone acetate (5 patients) and the independent data review committee (DRC) found the combination safe. The 50 mg BID of onapristone plus full dose abiraterone acetate dose level is current accruing patients in the UK and US, it is anticipated that the DRC will have safety data from first group of patients (maximum 6 patients) treated at the 50 mg BID dose of onapristone in combination with abiraterone acetate for review in September 2016.